Company / Operating Cash Flow
Zentalis Pharmaceuticals, Inc. Operating Cash Flow History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$207.8M
FY2025
5-year range
-$207.8M / -$163.8M
FY2024-FY2025
Trend
-26.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
-$208M in FY2025.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 26.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$207.8M | -26.9% |
| FY2024 | -$163.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026